IART (Integra LifeSciences Holdings Corporation) Stock Financials & Earnings

IARTIntegra LifeSciences Holdings Corporation

Mkt Cap$738M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$1.6B

Net Income (TTM)-$516M

EPS (TTM)-$6.75

Free Cash Flow (TTM)-$63M

Gross Margin51.7%

Op. Margin4.2%

Net Margin-31.6%

FCF Margin-3.8%

P/S Ratio (TTM)0.5x

P/E Ratio (TTM)—

YoY Rev Growth+1.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$381M	$233M	$36M
Q2 23	$381M	$207M	$13M
Q3 23	$382M	$218M	$27M
Q4 23	$397M	$226M	$36M
Q1 24	$369M	$207M	$4M
Q2 24	$418M	$226M	-$3M
Q3 24	$381M	$200M	-$8M
Q4 24	$443M	$249M	$36M
Q1 25	$383M	$194M	-$15M
Q2 25	$416M	$209M	-$513M
Q3 25	$402M	$226M	$40M
Q4 25	$435M	$215M	$556M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Revenue by Geography

Quarter	Asia Pacific	Europe	Rest Of World	United States	Rest Of The World
Q1 23	$50M	$41M	$18M	$271M	—
Q2 23	$48M	$37M	$19M	$277M	—
Q3 23	$49M	$42M	$22M	$270M	—
Q1 24	$50M	$42M	$22M	$256M	—
Q2 24	$46M	$41M	$21M	$310M	—
Q3 24	$37M	$34M	$19M	$290M	—
Q4 24	$44M	$42M	—	$336M	—
Q1 25	$45M	$35M	—	$282M	$20M
Q2 25	$48M	$43M	—	$306M	$19M
Q3 25	$43M	$43M	—	$296M	$21M
Q4 25	$54M	$42M	—	$320M	$19M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$307M	$0	$307M
Q2 23	$309M	$0	$309M
Q3 23	$274M	$0	$274M
Q4 23	$276M	$33M	$309M
Q1 24	$592M	$71M	$663M
Q2 24	$215M	$82M	$297M
Q3 24	$215M	$62M	$278M
Q4 24	$246M	$27M	$274M
Q1 25	$239M	$34M	$273M
Q2 25	$218M	$36M	$254M
Q3 25	$232M	$36M	$268M
Q4 25	$235M	$29M	$264M

Shares Outstanding

Revenue Per Employee

Revenue / Employee